S-1/A: HCW Biologics Seeks $5.6M Amid Nasdaq Delisting Threat

HCW Biologics Inc. files an S-1/A to raise up to $5.6 million through a public offering of common stock or pre-funded warrants, while addressing ongoing Nasdaq listing compliance issues.

Summary

• HCW Biologics Inc. is offering up to 13,625,304 shares of common stock or pre-funded warrants, aiming to raise approximately $5.6 million on a reasonable best efforts basis.
• The assumed public offering price is $0.411 per share, based on the Nasdaq closing price on April 20, 2026.
• The company is a clinical-stage biopharmaceutical firm developing fusion immunotherapeutics for chronic inflammation, cancer, and senescence-associated dysplasia.
• Key proprietary molecules include HCW9201 and HCW9206, which are commercial-ready reagents for immunotherapeutic production, with HCW9206 recently highlighted in a Science Advances publication for its potential in CAR-T cell therapies.
• Clinical development programs include HCW9302 (IL-2 fusion protein for alopecia areata, with the first patient dosed on November 17, 2025) and preclinical molecules HCW11-018b and HCW11-040.
• HCW11-006 is being developed through a corporate partnership with Beijing Trimmune Biotech Co., Ltd., with Phase 1 trials in China expected in mid-2027.
• The company faces Nasdaq non-compliance due to its minimum bid price falling below $1.00 per share, with a hearing scheduled for May 5, 2026, to appeal a delisting determination.
• Net proceeds from the offering, estimated at $5.2 million (assuming full subscription), will fund preclinical and clinical development, R&D, marketing, trade payables, and general corporate purposes.
• Certain directors and executive officers intend to purchase an aggregate of $430,000 of securities in this offering, and existing investors are expected to purchase an additional $170,000.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the significant financial risks, including ongoing Nasdaq non-compliance, substantial dilution from the offering, and the 'reasonable best efforts' nature of the capital raise, which indicates uncertainty in securing the full target amount. While there are promising scientific developments and experienced management, the immediate financial challenges overshadow these positives.

Positives

• Proprietary drug discovery platforms (TOBI and TRBC) are in place for developing novel fusion immunotherapeutics.
• Commercial-ready compounds HCW9201 and HCW9206 are available for immunotherapeutic production, with HCW9206 showing promise for CAR-T cell therapies as published in Science Advances on March 13, 2026.
• The first patient was dosed in a clinical trial for HCW9302 in alopecia areata on November 17, 2025, marking progress in clinical development.
• A strategic corporate partnership with Beijing Trimmune Biotech Co., Ltd. is advancing HCW11-006, with Phase 1 trials in China expected in mid-2027.
• The management team includes Dr. Hing C. Wong, Founder and CEO, who previously developed Anktiva (ALT-803), an immunotherapeutic sold for $1.0 billion and approved by the FDA in 2024.
• Insider participation in the offering, with directors and executive officers intending to purchase $430,000 of securities, demonstrates management's confidence.

Negatives

• The company is non-compliant with Nasdaq's minimum bid price requirement ($0.411 per share as of April 20, 2026), leading to a delisting risk and a hearing scheduled for May 5, 2026.
• The offering is on a 'reasonable best efforts' basis with no minimum proceeds, creating uncertainty regarding the actual amount of capital to be raised.
• New investors will experience immediate and substantial dilution of ($0.08) per share based on the assumed public offering price of $0.411.
• There is no established trading market for the Pre-Funded Warrants, which will limit their liquidity.
• The company does not anticipate paying cash dividends in the foreseeable future, meaning investor returns depend solely on stock price appreciation.
• An accumulated deficit of ($108,515,846) as of December 31, 2025, indicates significant historical losses.
• The company remains subject to a mandatory Nasdaq Panel Monitor for one year from February 26, 2026, due to prior non-compliance issues.

Risks

• The stock price may be volatile or decline regardless of operating performance, potentially resulting in substantial losses for investors.
• There is a significant risk of delisting from Nasdaq due to non-compliance with the minimum bid price requirement.
• Sales of substantial amounts of securities in the public market could depress the market price of common stock.
• Extreme price and volume fluctuations could lead to costly securities class action litigation.
• Investors in this offering will experience immediate and substantial dilution in the book value of their investment.
• Management will have broad discretion over the use of offering proceeds, which might not be applied in ways that increase investment value.
• The company may need to raise additional funds, which could result in further dilution or the issuance of securities with superior rights.
• Pre-Funded Warrants are speculative in nature, and an active trading market for them is not expected to develop, limiting liquidity.
• Trading of common stock may be limited, making it difficult for stockholders to sell their shares.
• FINRA sales practice requirements (Regulation Best Interest) may limit broker-dealers' willingness to recommend the company's securities.
• The offering itself may cause the trading price of common stock to decrease.
• There is a risk of disruption to current plans and operations if the company cannot obtain sufficient funding for its operations, including drug candidate development and commercialization.
• Uncertainty exists regarding the timing, costs, and outcome of regulatory review and FDA clearance for clinical trials.
• The company may face challenges in securing clinical sites, enrolling patients, and initiating clinical trials.
• There is no guarantee that clinical trials will demonstrate the safety and efficacy of drug candidates.
• The company relies on third parties to conduct clinical trials and for the manufacture of drug candidates, posing dependency risks.
• The cost and timing of building out a new headquarters, including a biologics manufacturing facility, carry risks of cost overruns and delays.
• The company's ability to obtain and maintain intellectual property rights is crucial and subject to challenges.
• The company's going concern assessment is a factor for investors to consider.

Future Outlook

The company intends to use the proceeds from this offering to fund the continued progress of its preclinical and clinical development, including trials for HCW9302, research and development costs, marketing efforts, and general corporate purposes. It also plans to expand business development programs, identify compounds for out-licensing, and expand its patent portfolio. The company expects to complete this offering no later than two business days following the commencement of sales, with a termination date of May 11, 2026, unless fully subscribed or terminated earlier. Trimmune, a corporate partner, intends to begin Phase 1 clinical trials for HCW11-006 in China in mid-2027.

Management Comments

• We want our products to improve patients healthspan as well as their quality of life, and possibly extend longevity.
• These findings support the Company's belief that HCW9206 is a leap forward in both clinical potential and manufacturing efficiency.
• Our clinical development and financing strategy consider business development transactions as a key component for our plans to develop breakthrough therapeutics.
• We regularly assess our product portfolio to determine if clinical development through a corporate partnership is the optimal means to advance clinical development and commercialization.

Industry Context

StockSavvy.ai notes that HCW Biologics operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, focusing on immunotherapeutics for chronic inflammation, cancer, and aging-related pathologies. The company's proprietary TOBI and TRBC platforms aim to differentiate its pipeline. The recent publication in Science Advances regarding HCW9206's potential in CAR-T cell therapies positions HCW Biologics at the forefront of innovative manufacturing techniques, a critical area for advanced cell therapies. The partnership with Beijing Trimmune Biotech Co., Ltd. for HCW11-006 demonstrates a strategy to leverage external resources for development and market access, common among smaller biotechs. However, the ongoing Nasdaq listing challenges highlight the financial pressures and market skepticism often faced by early-stage companies without significant revenue, contrasting with more established players in the oncology and immunology space.

Comparison to Industry Standards

• StockSavvy.ai observes that HCW Biologics' CEO, Dr. Hing C. Wong, has a strong track record, having developed Anktiva (ALT-803), an IL-15 agonist receptor, which was acquired by ImmunityBio, Inc. for $1.0 billion in 2017 and approved by the FDA in 2024 for bladder cancer. This compares favorably to industry standards for executive experience in successful drug development and commercialization.
• The company's focus on fusion immunotherapeutics and T-cell engagers (like HCW11-018b, the 'Big BiTE') aligns with cutting-edge oncology and immunology research, similar to companies like Amgen (with its BiTE platform, e.g., Blincyto) or Regeneron/Sanofi (with their bispecific antibodies). HCW Biologics aims to address manufacturability, safety, and solid tumor challenges, which are common hurdles for first-generation T-cell engagers.
• The preclinical data for HCW11-040, showing expansion of Tpex cells without cytokine storm and superior immune-cell activation compared to pembrolizumab (Keytruda), suggests a potentially differentiated profile against a blockbuster drug. This positions it against major pharmaceutical companies like Merck, which markets Keytruda.
• The Nasdaq minimum bid price non-compliance is a significant deviation from industry best practices for publicly traded companies, indicating financial instability and potential investor confidence issues, unlike larger, more stable biopharmaceutical firms.

Corporate Governance

Legal Proceedings

• Approximately $1.1 million of the offering proceeds are allocated for trade payables and the settlement of ongoing or potential litigation, indicating existing or anticipated legal matters without specific details.

Related Party Transactions

• Scott Garrett (Chairman) intends to purchase $250,000, Hing C. Wong (CEO) intends to purchase $160,000, and Rebecca Byam (CFO) intends to purchase $20,000 of securities in this offering.
• In a February 20, 2024 private placement, Rebecca Byam purchased 19,018 shares for $1,064,999.60; Dr. Hing C. Wong purchased 18,483 shares for $1,035,003.20; and Scott Garrett purchased 3,572 shares for $200,001.20.
• As of October 31, 2024, certain officers and directors purchased senior secured notes: Dr. Hing C. Wong ($2,405,000), Rebecca Byam ($220,000), Scott T. Garrett ($140,000), Gary M. Winer (former director, $60,000), Lee Flowers ($25,000), and Rick S. Greene ($25,000). These notes were later converted into common stock and warrants.
• As of May 5, 2025, Convertible Bridge Notes were issued to related parties: Hing C. Wong ($60,000), Scott T. Garrett ($100,000), and Gary M. Winer ($10,000). These notes were converted into common stock and rights to Wugen proceeds.
• Stock options have been granted to executive officers as part of their compensation arrangements.

Stakeholder Impact

• **Shareholders**: Will experience immediate and substantial dilution from the offering. Existing shareholders face potential further dilution from future equity issuances and the exercise of outstanding warrants. The Nasdaq delisting risk poses a significant threat to liquidity and investment value.
• **Employees**: Key personnel are incentivized through equity awards, but the company's financial challenges and Nasdaq compliance issues could create uncertainty regarding job security and long-term equity value.
• **Customers/Partners**: The company's focus on developing immunotherapeutics and its partnerships (e.g., Trimmune) suggest potential for future product development and market reach, which could benefit patients and collaborators if successful.
• **Creditors**: The allocation of offering proceeds to settle trade payables and potential litigation could benefit existing creditors. The conversion of previous secured notes impacted prior creditors by changing their investment vehicle.
• **Regulatory Bodies**: The company's ongoing Nasdaq compliance issues and SEC filings demonstrate its interaction with regulatory authorities, which could lead to increased scrutiny.

Next Steps

• The registration statement needs to become effective for the proposed sale to the public to commence.
• The offering is expected to be completed no later than two business days following the commencement of sales.
• The offering will terminate on May 11, 2026, unless fully subscribed or terminated earlier by the company.
• A hearing before a Nasdaq Hearings Panel is scheduled for May 5, 2026, to appeal the minimum bid price non-compliance.
• A Special Meeting of Stockholders is scheduled for April 27, 2026, to seek approval for the exercisability of 2026 Common Stock Warrants and the repricing of Inducement Warrants.
• Trimmune intends to begin Phase 1 clinical trials for HCW11-006 in China in mid-2027.
• The company will continue to monitor IND-enabling studies and clinical study results for HCW11-006 before deciding to exercise its Opt-In Right for the Americas market.
• The company intends to use offering proceeds to fund continued preclinical and clinical development, including HCW9302 trials, R&D, marketing, and general corporate purposes.

Key Dates

Recommendation

The filing reveals a company in a precarious financial and regulatory position. The 'reasonable best efforts' offering with no minimum, coupled with the immediate and substantial dilution for new investors, signals significant capital raising challenges. The ongoing Nasdaq non-compliance and delisting risk, despite recent efforts, create high uncertainty regarding the stock's future trading viability. While the company has promising preclinical assets and an experienced CEO, the current financial instability and the need for continuous capital raises without guaranteed success make this a high-risk investment with a strong likelihood of further share price depreciation. The accumulated deficit further underscores the long path to profitability.

Keywords

Biopharmaceutical, Immunotherapeutics, Clinical-stage, Cancer, Autoimmune disorders, Chronic inflammation, CAR-T cell therapy, Nasdaq compliance, Public offering, Pre-funded warrants, HCW Biologics, HCWB, Drug development, Biotechnology, SEC filing, S-1/A, Dilution